Jump to ContentJump to Main Navigation

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

12 Issues per year


IMPACT FACTOR increased in 2014: 3.268
Rank 106 out of 289 in category Biochemistry & Molecular Biology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing

Julie Chao1 / Bo Shen1 / Lin Gao1 / Chun-Fang Xia1 / Grant Bledsoe1 / Lee Chao1

1Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA

Corresponding author

Citation Information: Biological Chemistry. Volume 391, Issue 4, Pages 345–355, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: 10.1515/bc.2010.042, February 2010

Publication History

Received:
2009-10-16
Accepted:
2010-01-14
Published Online:
2010-02-24

Abstract

Tissue kallikrein (KLK1) processes low-molecular weight kininogen to produce vasoactive kinins, which exert biological functions via kinin receptor signaling. Using various delivery approaches, we have demonstrated that tissue kallikrein through kinin B2 receptor signaling exhibits a wide spectrum of beneficial effects by reducing cardiac and renal injuries, restenosis and ischemic stroke, and by promoting angiogenesis and skin wound healing, independent of blood pressure reduction. Protection by tissue kallikrein in oxidative organ damage is attributed to the inhibition of apoptosis, inflammation, hypertrophy and fibrosis. Tissue kallikrein also enhances neovascularization in ischemic heart and limb. Moreover, tissue kallikrein/kinin infusion not only prevents but also reverses kidney injury, inflammation and fibrosis in salt-induced hypertensive rats. Furthermore, there is a wide time window for kallikrein administration in protection against ischemic brain infarction, as delayed kallikrein infusion for 24 h after cerebral ischemia in rats is effective in reducing neurological deficits, infarct size, apoptosis and inflammation. Importantly, in the clinical setting, human tissue kallikrein has been proven to be effective in the treatment of patients with acute brain infarction when injected within 48 h after stroke onset. Finally, kallikrein promotes skin wound healing and keratinocyte migration by direct activation of protease-activated receptor 1.

Keywords: blood vessel; brain; heart; kidney; kinin B2 receptor; skin; tissue kallikrein

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Florian Guenther and Matthias F. Melzig
Journal of Pharmacy and Pharmacology, 2015, Page n/a
[2]
Wenya Lan, Fang Yang, Zhuangli Li, Ling Liu, Hongfei Sang, Yongjun Jiang, Yunyun Xiong, and Renliang Zhang
Journal of Vascular Surgery, 2015
[3]
Tae Kwon Kim, Lucas Tirloni, Zeljko Radulovic, Lauren Lewis, Mariam Bakshi, Creston Hill, Itabajara da Silva Vaz, Carlos Logullo, Carlos Termignoni, and Albert Mulenga
International Journal for Parasitology, 2015
[4]
Fabien Gueugnon, Aurélia Barascu, Konstantinos Mavridis, Agnès Petit-Courty, Sylvain Marchand-Adam, Valérie Gissot, Andreas Scorilas, Serge Guyetant, and Yves Courty
Tumor Biology, 2015
[5]
Domenico Regoli and Fernand Gobeil
Vascular Pharmacology, 2015, Volume 64, Page 1
[6]
Marta Martin-Lorenzo, Irene Zubiri, Aroa S. Maroto, Laura Gonzalez-Calero, Maria Posada-Ayala, Fernando de la Cuesta, Laura Mourino-Alvarez, Luis F. Lopez-Almodovar, Eva Calvo-Bonacho, Luis M. Ruilope, Luis R. Padial, Maria G. Barderas, Fernando Vivanco, and Gloria Alvarez-Llamas
Metabolomics, 2014
[7]
Yu-yu Yao, Cong Fu, Gen-shan Ma, Yi Feng, Cheng-xing Shen, Guo-qiu Wu, Xiao-guo Zhang, Jian-dong Ding, Cheng-chun Tang, Zhong Chen, Qi-ming Dai, Jia-yi Tong, Dan Luo, Jian Zhu, Hong Zhi, Yong-jun Li, Cheng-wei Ju, Jing Lu, Julie Chao, and Lee Chao
Clinica Chimica Acta, 2013, Volume 423, Page 90
[8]
Jagdish Narain Sharma
Asian Pacific Journal of Tropical Biomedicine, 2012, Volume 2, Number 3, Page S1938
[9]
Xinli Shao, Ru Yang, Mei Yan, Yajuan Li, Yong Du, Indu Raman, Bo Zhang, Ward Wakeland, Peter Igarashi, Chandra Mohan, and Quan-Zhen Li
Arthritis & Rheumatism, 2013, Volume 65, Number 3, Page 780
[10]
Virginia Roldós, Rodrigo J. Carbajo, Anne-Kathrin Schott, Antonio Pineda-Lucena, Laura Ochoa-Callejero, Alfredo Martínez, Ana Ramos, and Beatriz de Pascual-Teresa
European Journal of Medicinal Chemistry, 2012, Volume 55, Page 262
[11]
Domenico Regoli, Gerard E. Plante, and Fernand Gobeil
Pharmacology & Therapeutics, 2012, Volume 135, Number 1, Page 94
[12]
Joanna Koziel and Jan Potempa
Cell and Tissue Research, 2013, Volume 351, Number 2, Page 325
[13]
Pramod Gautam, Pankaj Jha, Dhirendra Kumar, Shivani Tyagi, Binuja Varma, Debasis Dash, Arijit Mukhopadhyay, and Mitali Mukerji
Human Genetics, 2012, Volume 131, Number 1, Page 131
[14]
Hui-Zhen Yu, Liang-di Xie, Peng-li Zhu, Chang-sheng Xu, and Hua-jun Wang
Molecular and Cellular Biochemistry, 2012, Volume 360, Number 1-2, Page 363
[15]
Ling Liu, Haibo Liu, Fang Yang, Guanghui Chen, Houguang Zhou, Min Tang, Renliang Zhang, and Qiang Dong
Biochemical and Biophysical Research Communications, 2011, Volume 407, Number 2, Page 283
[17]
Peter Goettig, Viktor Magdolen, and Hans Brandstetter
Biochimie, 2010, Volume 92, Number 11, Page 1546

Comments (0)

Please log in or register to comment.